What is systemic mastocytosis?
Systemic mastocytosis (SM) is a rare condition in which abnormal mast cells build up in the bone marrow and other organs. Mast cells are immune cells that release histamine and other chemicals during allergic reactions.
In SM, the mast cells come from a single faulty cell (they are clonal). In almost all adults, they carry a change in the KIT gene called D816V, which keeps them switched on and growing.
The extra mast cells release their chemicals too easily. This causes flushing, itching, stomach cramps, diarrhoea and, in some people, severe allergic reactions (anaphylaxis), for example after a wasp or bee sting.
Most adults have indolent systemic mastocytosis. It does not usually shorten life, but the symptoms can affect daily life a great deal. A smaller group has advanced SM, which damages organs and behaves like a blood cancer.
SM is classed by the World Health Organization as a myeloid neoplasm, in the same broad family as chronic myeloid blood cancers. Treatments range from antihistamines to targeted drugs such as avapritinib and midostaurin.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of disease | Clonal mast cell neoplasm (myeloid neoplasm) |
| How common | About 1 in 10,000 people; likely under-diagnosed |
| Typical age | Usually diagnosed at 30-60 |
| Sex | Men and women equally |
| Key gene change | KIT D816V in over 90% of adults |
| Main organs | Bone marrow, skin, bones, gut, liver and spleen |
| Key blood test | Raised serum tryptase, often above 20 ng/mL |
| Main treatments | Antihistamines and other mast cell stabilisers, adrenaline pens, bone protection, avapritinib, midostaurin, cladribine, stem cell transplant |
| Outlook | Indolent SM: near-normal life expectancy; advanced SM: months to a few years depending on type |
2. Types of mastocytosis
| Type | Main features | Behaviour |
|---|---|---|
| Cutaneous mastocytosis | Skin only; mostly in children | Often improves or clears by adolescence |
| Bone marrow mastocytosis | Marrow involvement without skin lesions; tryptase often lower | Indolent; high risk of severe sting reactions |
| Indolent SM (ISM) | The commonest adult form; usually with skin spots | Life expectancy close to normal |
| Smouldering SM (SSM) | High mast cell burden (“B-findings”), such as a large liver or spleen or very high tryptase | Slow, but higher risk of progression |
| Aggressive SM (ASM) | Organ damage (“C-findings”) such as low blood counts, liver dysfunction, bone destruction or malabsorption | A cancer needing treatment |
| SM with an associated haematological neoplasm (SM-AHN) | SM together with another blood cancer, often CMML or MDS | Outlook mostly depends on the other blood cancer |
| Mast cell leukaemia (MCL) | Mast cells make up 20% or more of marrow cells | Very rare and aggressive |
| Mast cell sarcoma | A solid tumour of very abnormal mast cells | Extremely rare and aggressive |
3. Causes and risk factors
| Factor | Notes |
|---|---|
| KIT D816V mutation | Acquired during life in a blood stem cell; not inherited in most cases |
| Other mutations | TET2, SRSF2, ASXL1 and RUNX1 changes are common in advanced SM and worsen the outlook |
| Family history | Familial cases are very rare |
| Hereditary alpha-tryptasaemia | An inherited extra copy of the tryptase gene, more common in people with SM, which may make reactions more severe |
4. How does it look?
4.1 On the skin
About 80% of adults with ISM have skin lesions.
| Feature | What it looks like |
|---|---|
| Spots | Small, round, red-brown or tan spots or slightly raised bumps, often on the thighs and trunk |
| Spread | Many spots, usually symmetrical, sparing the face, palms and soles |
| Darier sign | Rubbing a spot makes it red, swollen and itchy within minutes |
| Flushing | Sudden redness of the face, neck and chest |
| Old name | Urticaria pigmentosa; now called maculopapular cutaneous mastocytosis |
4.2 Inside the body and on scans
| Finding | What is seen |
|---|---|
| Bones | Thinning (osteoporosis), fractures of the spine, or areas of dense bone (osteosclerosis) on X-ray or DEXA scan |
| Liver and spleen | Enlargement on ultrasound or CT, mainly in smouldering and advanced SM |
| Lymph nodes | Swollen nodes in some people |
| Gut | Inflammation or poor absorption in advanced disease |
4.3 Under the microscope
| Feature | What the pathologist sees |
|---|---|
| Bone marrow | Dense clusters of 15 or more mast cells, often next to blood vessels or bony trabeculae |
| Cell shape | Spindle-shaped, atypical mast cells instead of round ones |
| Stains | Tryptase and CD117 (KIT) positive; abnormal CD25, CD2 or CD30 expression |
| Genetic test | Sensitive PCR shows KIT D816V |
5. Symptoms
Symptoms vary a lot from person to person. Many are caused by chemicals released from mast cells, others by the build-up of cells in organs.
5.1 Mast cell mediator symptoms
| Area | Symptoms |
|---|---|
| Skin | Itching, flushing, hives, red-brown spots that swell when rubbed |
| Gut | Stomach cramps, nausea, heartburn, diarrhoea |
| Heart and circulation | Fast heartbeat, light-headedness, low blood pressure and fainting |
| Breathing | Wheezing or throat tightness during reactions |
| Brain | Headaches, poor concentration (“brain fog”), low mood |
| Whole body | Tiredness, bone and muscle pain |
| Anaphylaxis | Sudden, severe reactions, often after insect stings, some drugs, anaesthetics, alcohol, heat or exercise |
5.2 Common triggers
| Trigger | Examples |
|---|---|
| Insect stings | Wasps, bees and hornets; the commonest cause of severe reactions |
| Physical factors | Heat, sudden temperature change, friction, pressure, vigorous exercise |
| Medicines | Some painkillers (aspirin, other NSAIDs, opioids), some anaesthetic drugs, contrast dye for X-rays |
| Food and drink | Alcohol, spicy food and very hot drinks in some people |
| Emotional stress | Anxiety and lack of sleep |
| Infections | Colds and other infections can worsen symptoms |
Triggers differ between people, and many people tolerate some of these without problems. Keeping a symptom diary helps identify personal triggers.
5.3 Symptoms of advanced SM
| Symptom | Cause |
|---|---|
| Tiredness, infections, bruising | Low blood counts from marrow failure |
| Swollen tummy | Enlarged liver or spleen, fluid in the abdomen (ascites) |
| Weight loss and diarrhoea | Poor absorption of food |
| Bone pain and fractures | Bone destruction |
| Yellow skin | Liver damage |
5.4 When to see a doctor
See a doctor if you have repeated flushing, unexplained hives, red-brown skin spots that itch when rubbed, or fainting after a sting. Anyone with a severe allergic reaction should get emergency help and later be tested.
6. Diagnosis
6.1 Tests
| Test | Why it is done |
|---|---|
| Serum tryptase | Raised in most people with SM; a level above 20 ng/mL is a diagnostic criterion |
| Skin biopsy | Confirms mastocytosis in the skin |
| KIT D816V test on blood | A sensitive blood test that often detects the mutation |
| Bone marrow biopsy | The key test; shows mast cell clusters, CD25 expression and the subtype |
| Full blood count and liver tests | Look for organ damage |
| DEXA scan and X-rays | Check bone health |
| Ultrasound or CT | Check liver, spleen and lymph nodes |
| Gene panel | Looks for other mutations in advanced SM |
6.2 WHO diagnostic criteria
SM is diagnosed when there is one major and at least one minor criterion, or three minor criteria.
| Criterion | Requirement |
|---|---|
| Major | Multifocal dense clusters of 15 or more mast cells in bone marrow or another organ outside the skin |
| Minor 1 | More than 25% of mast cells are spindle-shaped or atypical |
| Minor 2 | An activating KIT mutation, usually D816V |
| Minor 3 | Mast cells express CD25, CD2 and/or CD30 |
| Minor 4 | Serum tryptase persistently above 20 ng/mL (adjusted if hereditary alpha-tryptasaemia is present) |
6.3 Mastocytosis and mast cell activation syndrome
Mast cell activation syndrome (MCAS) is a related but different diagnosis. In MCAS, people have repeated episodes of mast cell symptoms with a measurable rise in tryptase during attacks, and the symptoms improve with mast cell medicines.
Systemic mastocytosis is one cause of MCAS, but MCAS can also happen with normal, non-clonal mast cells, for example in people with severe allergies. A bone marrow test separates the two.
7. Treatment
7.1 Symptom control for all types
| Treatment | Purpose |
|---|---|
| H1 antihistamines (for example cetirizine, fexofenadine) | Itching, flushing, hives |
| H2 blockers (for example famotidine) | Stomach pain, acid and diarrhoea |
| Oral cromolyn sodium | Gut symptoms |
| Leukotriene blockers (montelukast) | Additional symptom control |
| Omalizumab | Repeated anaphylaxis despite other treatment |
| Adrenaline auto-injectors | Carry two at all times for anaphylaxis |
| Venom immunotherapy | Lifelong, for people who have reacted to insect stings |
| Bone protection | Calcium, vitamin D, bisphosphonates or denosumab |
| Trigger avoidance | Heat, friction, alcohol and some drugs; tell anaesthetists before operations |
7.2 Disease-directed treatment
Drugs that act on the abnormal mast cells themselves are used for advanced SM, and for indolent SM when symptoms stay severe despite the medicines above. Avapritinib was approved for indolent SM in 2023, after a placebo-controlled trial showed better symptom scores and large falls in tryptase.
| Treatment | Who it is for | Notes |
|---|---|---|
| Avapritinib | ISM with moderate-severe symptoms (low dose); advanced SM (higher dose) | Targets KIT D816V; reduces symptoms, tryptase and mast cells |
| Midostaurin | Advanced SM | Multi-kinase inhibitor; responses in about 60% |
| Cladribine | Advanced SM, or ISM with severe symptoms | Chemotherapy given in short courses |
| Interferon alfa | Selected patients, including bone disease | Older option with more side effects |
| Treatment of the associated cancer | SM-AHN | For example azacitidine for CMML or MDS |
| Allogeneic stem cell transplant | Fit patients with advanced SM | The only potentially curative option |
8. Side effects of treatment
| Treatment | Possible effects |
|---|---|
| Antihistamines | Drowsiness with older types |
| Avapritinib | Swelling around the eyes, memory problems, low blood counts, rare bleeding in the brain (mainly at higher doses and low platelets) |
| Midostaurin | Nausea, vomiting, diarrhoea |
| Cladribine | Low blood counts, infections |
| Stem cell transplant | Serious infections and graft-versus-host disease |
9. Outlook
| Type | Approximate median survival |
|---|---|
| Indolent and bone marrow SM | Close to normal life expectancy; progression in under 5% |
| Smouldering SM | Several years to decades, but shorter than indolent SM |
| Aggressive SM | About 3-4 years historically, likely improving with new drugs |
| SM-AHN | About 2 years, depending on the associated cancer |
| Mast cell leukaemia | Months historically; better with modern targeted drugs and transplant |
10. Living with systemic mastocytosis
Many people with ISM live full lives once symptoms are controlled. Key steps include:
- Carrying two adrenaline pens and an emergency card or bracelet
- Knowing and avoiding personal triggers
- Telling surgeons, dentists and anaesthetists before procedures
- Having regular bone density scans
- Having blood tests, including tryptase, about once a year, or more often in advanced SM
Specialist mastocytosis centres, often linked to the European Competence Network on Mastocytosis, offer coordinated care from haematologists, dermatologists and allergists.
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is mastocytosis an allergy? | No, but mast cells react too easily, so allergy-like symptoms are common |
| Is it cancer? | It is classed as a myeloid neoplasm. Indolent SM behaves more like a long-term condition; advanced SM is treated like a blood cancer |
| Will my children get it? | Very unlikely; it is usually not inherited |
| Can I have an operation? | Yes, with planning; anaesthetists give premedication and avoid trigger drugs |
| Can I drink alcohol? | Some people can; others find it triggers flushing and should avoid it |
12. Questions to ask your care team
- Which type of mastocytosis do I have, and what is my tryptase level?
- Should I carry adrenaline pens, and how many?
- Do I need venom immunotherapy?
- How often should my bones be checked?
- Would avapritinib or another targeted drug help my symptoms?
- What should I tell my dentist, surgeon or anaesthetist?
Resources
- Valent, P. et al. (2021) ‘Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal’, HemaSphere, 5(11), e646.
- Khoury, J.D. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms’, Leukemia, 36(7), pp. 1703-1719.
- Lim, K.H. et al. (2009) ‘Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors’, Blood, 113(23), pp. 5727-5736.
- Pardanani, A. (2023) ‘Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management’, American Journal of Hematology, 98(7), pp. 1097-1116.
- Gotlib, J. et al. (2016) ‘Efficacy and safety of midostaurin in advanced systemic mastocytosis’, New England Journal of Medicine, 374(26), pp. 2530-2541.
- Gotlib, J. et al. (2021) ‘Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial’, Nature Medicine, 27(12), pp. 2192-2199.
- Gotlib, J. et al. (2023) ‘Avapritinib versus placebo in indolent systemic mastocytosis’, NEJM Evidence, 2(6), EVIDoa2200339.
- Valent, P. et al. (2014) ‘Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis’, Allergy, 69(10), pp. 1267-1274.
Prepared by the editorial team, October 2026.